ZIF-C for targeted RNA interference and CRISPR/Cas9 based gene editing in prostate cancer

Arpita Poddar; Suneela Pyreddy; Francesco Carraro; Sudip Dhakal; Andrea Rassell; Matthew R. Field; T. Srinivasa Reddy; Paolo Falcaro; Cara M. Doherty; Ravi Shukla

doi:10.1039/D0CC06241C

ZIF-C for targeted RNA interference and CRISPR/Cas9 based gene editing in prostate cancer†

Arpita Poddar,

^ab Suneela Pyreddy,

^a Francesco Carraro,

^c Sudip Dhakal,

^a Andrea Rassell,^a Matthew R. Field,

^d T. Srinivasa Reddy,

^a Paolo Falcaro,

^c Cara M. Doherty

^b and Ravi Shukla

*^a

Author affiliations

* Corresponding authors

^a Ian Potter NanoBiosensing Facility, NanoBiotechnology Research Laboratory (NBRL), School of Science, RMIT University, Melbourne, Victoria 3001, Australia
E-mail: ravi.shukla@rmit.edu.au

^b CSIRO Manufacturing, Clayton, Victoria 3168, Australia

^c Institute of Physical and Theoretical Chemistry, Graz University of Technology, 8010 Graz, Austria

^d RMIT Microscopy & Microanalysis Facility, RMIT University, Melbourne, Victoria 3001, Australia

Abstract

Gene therapy is highly suited for prostate cancer (PC). Metal–organic-frameworks (MOFs) are potential gene delivery systems. Target-specific cytoplasmic and nuclear knockdown in host gene expression using ZIF-C is shown for the first time through RNAi and CRISPR/Cas9 based gene editing in PC cells. A green tea phytochemical coating enhances intracellular delivery.

Chemical Communications

ZIF-C for targeted RNA interference and CRISPR/Cas9 based gene editing in prostate cancer†

Abstract

Supplementary files

Article information

Download Citation

Permissions

ZIF-C for targeted RNA interference and CRISPR/Cas9 based gene editing in prostate cancer

Social activity

Search articles by author

Spotlight

Advertisements